Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

Am J Psychiatry. 1995 Jan;152(1):130-4. doi: 10.1176/ajp.152.1.130.


Objective: The authors assessed the effects on primary negative symptoms of low doses of amisulpride, a substituted benzamide neuroleptic with high affinity for D2 and D3 dopamine receptors.

Method: Young, drug-free schizophrenic patients with pure negative symptoms participated in a 6-week double-blind trial of placebo (N = 10) or low-dose amisulpride (N = 10). They were assessed with the Scale for the Assessment of Negative Symptoms.

Results: Amisulpride significantly improved negative symptoms. Improvement in avolition, attentional impairment, and retardation was significantly greater with amisulpride than with placebo.

Conclusions: These findings suggest that some primary negative symptoms may be directly affected by low doses of benzamide neuroleptics.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amisulpride
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Placebos
  • Psychiatric Status Rating Scales
  • Psychotropic Drugs / therapeutic use*
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Sulpiride / analogs & derivatives*
  • Sulpiride / therapeutic use
  • Treatment Outcome


  • Placebos
  • Psychotropic Drugs
  • Sulpiride
  • Amisulpride